高剂量的N-乙半氨酸对轻度至中度COPD患者的恶化和肺功能的影响:双盲,并行组,多中心随机临床试验
Yumin Zhou1,2, Fan Wu1,2, Zhe Shi3
1State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Nature communications
|September 30, 2024
概括
在两年内,N-乙半氨酸在轻度至中度慢性阻塞性肺病 (COPD) 患者中没有显著减少恶化或改善肺功能. 这项研究发现,这种抗氧化剂和粘菌剂在COPD管理中没有益处.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 对于治疗轻度至中度慢性阻塞性肺病 (COPD) 的证据有限.
- 作为抗氧化剂和解剂的N-乙半氨酸对COPD患者的疗效仍然不确定.
- 高剂量的N-乙半氨酸对COPD恶化和肺功能的长期影响需要进一步研究.
研究的目的:
- 评估N-乙半氨酸在减轻恶化和改善COPD轻度至中度患者肺功能方面的疗效.
- 与安慰剂相比,评估使用N-乙半氨酸 (每天两次600毫克) 治疗两年的影响.
主要方法:
- 一个多中心,随机,双盲,安慰剂对照试验,涉及968名患有轻度至中度COPD的患者.
- 患者接受N-乙半氨酸或安慰剂两年,每三个月评估一次恶化和每年一次肺功能 (FEV1).
- 首要结局包括总恶化的年率和24个月使用支气管扩展剂之前FEV1的变化.
主要成果:
- 在N-乙半氨酸组 (0.65患者/年) 和安慰剂组 (0.72患者/年) 之间,总恶化的年率没有显著差异 (RR,0.90;P=0.10).
- 在两个组之间24个月后,在使用支气管扩展剂之前,没有观察到与基线FEV1的变化有显著差异.
- 在这种患者群体中,高剂量的N-乙半氨酸治疗并没有显著降低恶化率或改善肺功能.
结论:
- 长期,高剂量的N-乙半氨酸治疗在减少轻度至中度COPD患者总恶化病例的年率方面没有效果.
- 在两年内,N-乙半氨酸在轻度至中度COPD患者的肺功能 (FEV1) 中没有显著改善.
- 这些发现表明,N-乙半氨酸不是一种有益的治疗方法,用于管理轻度至中度的COPD,在恶化和肺功能方面.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
188
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
188
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
246
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
246
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
01:29Acute Respiratory Failure-V
125
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
125
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K